CN Patent

CN1874776A — 治疗慢性骨髓性白血病(cml)的4－苯胺基－3－喹啉腈

Assigned to Wyeth LLC · Expires 2006-12-06 · 19y expired

What this patent protects

式(I)化合物，其中n为1－3的整数；X为N、CH，前提是当X为N时n为2或3；R为具有1到3个碳原子的烷基；R 1 为2，4－二CI、5－OMe；2，4－二CI；3，4，5－三OMe；3－CI、5－OMe；2－Me、5－OMe；2，4－二－Me；2，4－二Me－5－OMe、2，4－二CI、5－OEt；R 2 为具有1到2个碳原子的烷基；及其医药上可接受的盐适用于治疗慢性骨髓性白血病(CML)。

USPTO Abstract

式(I)化合物，其中n为1－3的整数；X为N、CH，前提是当X为N时n为2或3；R为具有1到3个碳原子的烷基；R 1 为2，4－二CI、5－OMe；2，4－二CI；3，4，5－三OMe；3－CI、5－OMe；2－Me、5－OMe；2，4－二－Me；2，4－二Me－5－OMe、2，4－二CI、5－OEt；R 2 为具有1到2个碳原子的烷基；及其医药上可接受的盐适用于治疗慢性骨髓性白血病(CML)。

Drugs covered by this patent

bosutinib-monohydrate (BOSUTINIB MONOHYDRATE)

Patent Metadata

Patent number: CN1874776A
Jurisdiction: CN
Classification: —
Expires: 2006-12-06
Drug substance claim: No
Drug product claim: No
Assignee: Wyeth LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.